Nuvation Bio reports updated Phase II J201 data for safusidenib
Nuvation Bio has reported updated long-term follow-up findings from the Phase II J201 trial of safusidenib in patirnts with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma.
The post Nuvation Bio reports updated Phase II J201 data for safusidenib appeared first on Clinical Trials Arena .